Travere Therapeutics Stock Price Down 4 percent - MarketBeat
| TVTX Stock | USD 19.57 0.76 4.04% |
Slightly above 54% of Travere Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that some traders are interested. Travere Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Travere Therapeutics' earnings reports, geopolitical events, and overall market trends.
Travere |
Travere Therapeutics Stock Price Down 4 MarketBeat
Read at news.google.com
 |
Travere Therapeutics Fundamental Analysis
We analyze Travere Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Travere Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Travere Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.
Peers
Travere Therapeutics Related Equities
| APLS | Apellis Pharmaceuticals | 4.39 | ||||
| LEGN | Legend Biotech | 2.95 | ||||
| GPCR | Structure Therapeutics | 2.38 | ||||
| IDYA | Ideaya Biosciences | 0.33 | ||||
| AKRO | Akero Therapeutics | 0.28 | ||||
| STOK | Stoke Therapeutics | 0.33 | ||||
| COGT | Cogent Biosciences | 0.42 | ||||
| PTGX | Protagonist Therapeutics | 1.23 | ||||
| KROS | Keros Therapeutics | 1.75 | ||||
| MGTX | MeiraGTx Holdings | 1.92 | ||||
| ANAB | AnaptysBio | 2.32 | ||||
| CYTK | Cytokinetics | 2.37 | ||||
| NUVL | Nuvalent | 2.49 | ||||
| PCVX | Vaxcyte | 2.90 | ||||
| RNA | Avidity Biosciences | 4.02 | ||||
| VTYX | Ventyx Biosciences | 5.97 | ||||
| RVMD | Revolution Medicines | 10.46 |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.